Phase II trial of a low dose nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer.
Latest Information Update: 22 Apr 2019
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Registrational; Therapeutic Use
- 18 Apr 2019 Status changed from active, no longer recruiting to completed.
- 01 Dec 2018 Results (n=37, data cut off april 2018) published in the Anticancer Research.
- 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.